Literature DB >> 22059195

Representations of OxyContin in North American newspapers and medical journals.

Emma Whelan1, Mark Asbridge, Susan Haydt.   

Abstract

BACKGROUND: There are public concerns regarding OxyContin (Purdue Pharma, Canada) and charges within the pain medicine community that media coverage of the drug has been biased.
OBJECTIVE: To analyze and compare representations of OxyContin in medical journals and North American newspapers in an attempt to shed light on how each contributes to the 'social problem' associated with OxyContin.
METHODS: Using searches of newspaper and medical literature databases, two samples were drawn: 924 stories published between 1995 and 2005 in 27 North American newspapers, and 197 articles published between 1995 and 2007 in 33 medical journals in the fields of addiction/substance abuse, pain/anesthesiology and general/internal medicine. The foci, themes, perspectives represented and evaluations of OxyContin presented in these texts were analyzed statistically.
RESULTS: Newspaper coverage of OxyContin emphasized negative evaluations of the drug, focusing on abuse, addiction, crime and death rather than the use of OxyContin for the legitimate treatment of pain. Newspaper stories most often conveyed the perspectives of law enforcement and courts, and much less often represented the perspectives of physicians. However, analysis of physician perspectives represented in newspaper stories and in medical journals revealed a high degree of inconsistency, especially across the fields of pain medicine and addiction medicine.
CONCLUSION: The prevalence of negative representations of OxyContin is often blamed on biased media coverage and an ignorant public. However, the proliferation of inconsistent messages regarding the drug from physicians plays a role in the drug's persistent status as a social problem.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22059195      PMCID: PMC3202377          DOI: 10.1155/2011/867326

Source DB:  PubMed          Journal:  Pain Res Manag        ISSN: 1203-6765            Impact factor:   3.037


  13 in total

1.  Use of OxyContin by adolescent students.

Authors:  Edward M Adlaf; Angela Paglia-Boak; Bruna Brands
Journal:  CMAJ       Date:  2006-04-25       Impact factor: 8.262

Review 2.  Opioid guidelines in the management of chronic non-cancer pain.

Authors:  Andrea M Trescot; Mark V Boswell; Sairam L Atluri; Hans C Hansen; Timothy R Deer; Salahadin Abdi; Joseph F Jasper; Vijay Singh; Arthur E Jordan; Benjamin W Johnson; Roger S Cicala; Elmer E Dunbar; Standiford Helm; Kenneth G Varley; P K Suchdev; John R Swicegood; Aaron K Calodney; Bentley A Ogoke; W Stephen Minore; Laxmaiah Manchikanti
Journal:  Pain Physician       Date:  2006-01       Impact factor: 4.965

3.  Hawaii Board of Medical Examiners: pain management policy.

Authors: 
Journal:  Hawaii Med J       Date:  2006-03

Review 4.  Pharmacologic management of neuropathic pain: evidence-based recommendations.

Authors:  Robert H Dworkin; Alec B O'Connor; Miroslav Backonja; John T Farrar; Nanna B Finnerup; Troels S Jensen; Eija A Kalso; John D Loeser; Christine Miaskowski; Turo J Nurmikko; Russell K Portenoy; Andrew S C Rice; Brett R Stacey; Rolf-Detlef Treede; Dennis C Turk; Mark S Wallace
Journal:  Pain       Date:  2007-10-24       Impact factor: 6.961

5.  Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.

Authors:  Theodore J Cicero; James A Inciardi; Alvaro Muñoz
Journal:  J Pain       Date:  2005-10       Impact factor: 5.820

6.  The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society.

Authors: 
Journal:  Clin J Pain       Date:  1997-03       Impact factor: 3.442

Review 7.  Use of opioid analgesics for the treatment of chronic noncancer pain--a consensus statement and guidelines from the Canadian Pain Society, 2002.

Authors:  Roman D Jovey; Jeffrey Ennis; Jacqueline Gardner-Nix; Brian Goldman; Helen Hays; Mary Lynch; Dwight Moulin
Journal:  Pain Res Manag       Date:  2003       Impact factor: 3.037

8.  Model policy for the use of controlled substances for the treatment of pain.

Authors: 
Journal:  J Pain Palliat Care Pharmacother       Date:  2005

9.  Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Authors:  Joseph Pergolizzi; Rainer H Böger; Keith Budd; Albert Dahan; Serdar Erdine; Guy Hans; Hans-Georg Kress; Richard Langford; Rudolf Likar; Robert B Raffa; Paola Sacerdote
Journal:  Pain Pract       Date:  2008-05-23       Impact factor: 3.183

Review 10.  Public policy statement on the rights and responsibilities of health care professionals in the use of opioids for the treatment of pain: a consensus document from the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine.

Authors: 
Journal:  Pain Med       Date:  2004-09       Impact factor: 3.750

View more
  4 in total

1.  Trends in high-dose opioid prescribing in Canada.

Authors:  Tara Gomes; Muhammad M Mamdani; J Michael Paterson; Irfan A Dhalla; David N Juurlink
Journal:  Can Fam Physician       Date:  2014-09       Impact factor: 3.275

2.  Exploring the lived experience of adults using prescription opioids to manage chronic noncancer pain.

Authors:  Erica A Brooks; Anita Unruh; Mary E Lynch
Journal:  Pain Res Manag       Date:  2015-01-06       Impact factor: 3.037

3.  The American chronic pain crisis and the media: about time to get it right?

Authors:  Michael E Schatman
Journal:  J Pain Res       Date:  2015-12-17       Impact factor: 3.133

4.  Trends and changes in prescription opioid analgesic dispensing in Canada 2005-2012: an update with a focus on recent interventions.

Authors:  Benedikt Fischer; Wayne Jones; Jürgen Rehm
Journal:  BMC Health Serv Res       Date:  2014-02-26       Impact factor: 2.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.